AAOI
Applied Optoelectronics, Inc.
AAOI lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
SURG
SurgePays, Inc.
There isn't enough reported data to score SURG yet.
AAOI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
AAOI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SURG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
SURG's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
AAOI PE Valuation
AAOI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
SURG PE Valuation
SURG has no meaningful PE right now: it lost money over the past year.
AAOI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
AAOI has the edge over SURG on the outlook, with more favorable revenue expectations.
SURG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SURG's losses to shrink, with revenue holding steady.
AAOI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.98 | — |
| Q3 2026 | -$0.42 | +$3.02 |
| Q2 2026 | -$0.77 | +$2.81 |
| Q1 2026 | -$0.65 | +$3.43 |
| Q4 2025 | -$0.64 | +$3.86 |
| Q3 2025 | -$3.44 | -$1.41 |
| Q2 2025 | -$3.58 | -$1.70 |
| Q1 2025 | -$4.08 | -$2.29 |
| Q4 2024 | -$4.50 | -$2.75 |
AAOI has the edge over SURG on earnings, with more consistent year-over-year improvement.
SURG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$1.02 |
| Q1 2026 | -$1.93 | +$0.91 |
| Q4 2025 | -$1.80 | +$0.59 |
| Q3 2025 | -$2.19 | -$1.05 |
| Q2 2025 | -$2.54 | -3275% |
| Q1 2025 | -$2.84 | -349% |
| Q4 2024 | -$2.39 | -273% |
| Q3 2024 | -$1.14 | -179% |
SURG is still losing money, but far less than before: $1.52 per share over the past year, against $5.50 at its worst in early 2021.
AAOI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $269.9M | +127% |
| Q2 2026 | $191.9M | +86% |
| Q1 2026 | $151.1M | +51% |
| Q4 2025 | $134.3M | +34% |
| Q3 2025 | $118.6M | +82% |
| Q2 2025 | $103M | +138% |
| Q1 2025 | $99.9M | +146% |
| Q4 2024 | $100.3M | +66% |
AAOI has the edge over SURG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.5% | +15 points |
| Q2 2026 | -13% | +2.6 points |
| Q1 2026 | -8.6% | +0.3 points |
| Q4 2025 | -8.6% | -2.1 points |
| Q3 2025 | -15% | +10 points |
| Q2 2025 | -16% | +45 points |
| Q1 2025 | -8.9% | +44 points |
| Q4 2024 | -6.5% | +1 points |
AAOI's operating margin was −0.5% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
SURG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.2M | +41% |
| Q1 2026 | $16M | +51% |
| Q4 2025 | $16.2M | +69% |
| Q3 2025 | $18.7M | +292% |
| Q2 2025 | $11.5M | -24% |
| Q1 2025 | $10.6M | -66% |
| Q4 2024 | $9.6M | -70% |
| Q3 2024 | $4.8M | -86% |
SURG's revenue is recovering but still below its 2022 peak: $16M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | +80 points |
| Q1 2026 | -70% | +1.6 points |
| Q4 2025 | -79% | +113 points |
| Q3 2025 | -37% | +262 points |
| Q2 2025 | -59% | +13 points |
| Q1 2025 | -72% | -77 points |
| Q4 2024 | -192% | -194 points |
| Q3 2024 | -299% | -320 points |
SURG has the edge over AAOI on profitability, with a higher operating margin.
AAOI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$369.9M | -$291.2M |
| Q2 2026 | -$265.3M | -$174.4M |
| Q1 2026 | -$143.6M | -$64.3M |
| Q4 2025 | -$104.6M | -$51.6M |
| Q3 2025 | -$78.7M | -$58M |
| Q2 2025 | -$91M | -$86M |
| Q1 2025 | -$79.3M | -$45.1M |
| Q4 2024 | -$53M | -$48.4M |
SURG has the stronger cash trend. Its trailing FCF is down 63% versus its history, compared with AAOI at down 676%.
SURG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.6M | +$2.4M |
| Q3 2025 | -$4.6M | +$8.7M |
| Q2 2025 | -$6.1M | -$2M |
| Q1 2025 | -$7M | -272% |
| Q4 2022 | $4.7M | +$12.9M |
| Q3 2022 | -$801.2K | +$1.5M |
| Q2 2022 | $175.5K | +$1.6M |
SURG has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
AAOI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.7% | +6.3M shares |
| 1 year | +39% | +24.5M shares |
| 3 years | +168% | +55.1M shares |
| 5 years | +224% | +60.7M shares |
| Available history | +340% | +67.9M shares |
AAOI has 88M diluted shares, up 39% from a year ago.
SURG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.4% | +2.2M shares |
| 1 year | +29% | +5.9M shares |
| 3 years | +109% | +13.5M shares |
| 5 years | +1122% | +23.8M shares |
SURG has the edge over AAOI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
AAOI Net Leverage
AAOI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SURG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -2.2x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.3x | Net Cash |
| Q2 2023 | 0.0x | Very low |
| Q1 2023 | -0.3x | Net Cash |
| Q4 2022 | 0.4x | Very low |
SURG has more cash than debt.
AAOI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 4.8 | Oversold |
AAOI's weekly RSI is 35 (neutral) and its Stochastic is 5 (oversold).
SURG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 13.7 | Oversold |
SURG's weekly RSI is 32 (neutral) and its Stochastic is 14 (oversold).
AAOI PE vs Technology Sector
AAOI has no meaningful PE right now: it lost money over the past year.
SURG PE vs Technology Sector
| Metric | SURG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SURG has no meaningful PE right now: it lost money over the past year.
AAOI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.2 | 34% below |
| 20 week MA | $100.6 | 47% below |
| 50 week MA | $100.3 | 47% below |
| 100 week MA | $62.3 | 15% below |
| 200 week MA | $36.9 | 43% above |
AAOI has fallen below most of its moving averages, though it's still 43% above its 200-week average.
SURG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.14 | 0% above |
| 20 week MA | $0.21 | 33% below |
| 50 week MA | $0.65 | 78% below |
| 100 week MA | $1.50 | 91% below |
| 200 week MA | $3.02 | 95% below |
SURG is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
AAOI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $8.77 | -24% |
| 2021 | $8.77 | $5.64 | -36% |
| 2022 | $5.64 | $1.95 | -65% |
| 2023 | $1.95 | $19.3 | +891% |
| 2024 | $19.3 | $37.7 | +95% |
| 2025 | $37.7 | $37.2 | -1.5% |
| 2026 YTD | $37.2 | $52.9 | +42% |
AAOI has the edge over SURG on returns for 2026, with the stronger performance.
SURG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $6.00 | -59% |
| 2021 | $6.00 | $2.31 | -62% |
| 2022 | $2.31 | $6.29 | +172% |
| 2023 | $6.29 | $6.45 | +2.5% |
| 2024 | $6.45 | $1.83 | -72% |
| 2025 | $1.83 | $1.68 | -8.2% |
| 2026 YTD | $1.68 | $0.14 | -92% |
SURG's yearly returns have swung widely, from +172% in 2022 to −72% in 2024. It's down 92% so far in 2026.